BioCorRx Inc (OTCQB: BICX) CEO Brady Granier tells Proactive Investors the California-based developer of substance use disorders treatments has been awarded a $5.7 million, two-year grant from the National Institutes of Health for the development of BICX102, the company’s sustained release naltrexone implant for the treatment of opioid use addiction and alcoholism.
Granier says once the implant is approved, he envisions the company attaching its cognitive behavioral therapy and peer support program to provide more tools for physicians prescribing the product.